March 17, 2020 / 2:27 PM / in 15 days

BRIEF-Mabion Announces Financing Plan Following New Regulations Strategy For MabionCD20 Drug With EMA

March 17 (Reuters) - Mabion SA:

* SAID ON MONDAY IT HAS STARTED DISCUSSION ON COMPANY FINANCING WITH REGARD TO NEW REGULATIONS STRATEGY FOR MABIONCD20 DRUG WITH EMA

* SAID IT HAS RECEIVED SUPPORTING DOCUMENTS FROM ITS SHAREHOLDERS IN WHICH THEY DECLARE TO INCREASE COMPANY’S CAPITAL BY NO LESS THAN 15 MILLION ZLOTYS IN 2020

* THE CAPITAL INCREASE WILL BE IMPLEMENTED BY ACQUISITION OF SHARES UNDER NEW ISSUE OR BY USING DEBT INSTRUMENTS

* SAID HAS ACCEPTED THE SUPPORTING DOCUMENTS AND RESOLVED TO TAKE ACTIONS AIMED AT OBTAINING DEBT FINANCING, WHICH WILL ENABLE SUCCESSFUL IMPLEMENTATION OF NEW REGULATIONS STRATEGY FOR REGISTERING MABIONCD20 WITH EMA

* SAID CAPITAL SUPPLY AND DEBT FINANCING SHOULD GUARANTEE APPROVAL OF THE MEDICINE FOR MARKETING IN BOTH THE EU AND THE US

* SAID IT DOES NOT EXCLUDE SEEKING AND USING OTHER SOURCES OF FINANCING FOR DEVELOPMENT OF NEW PROJECTS

Source text for Eikon:

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below